|Publication Type||Journal Article|
|Year of Publication||2002|
|Authors||Shipp, MA, Ross, KN, Tamayo, P, Weng, AP, Kutok, JL, Aguiar, RCT, Gaasenbeek, M, Angelo, M, Reich, M, Pinkus, GS, Ray, TS, Koval, MA, Last, KW, Norton, A, Lister, AT, Mesirov, J|
|Pages||68 - 74|
|Keywords||Antineoplastic Combined Chemotherapy Protocols, Artificial Intelligence, B-Cell, Cancer, Cyclophosphamide, Diffuse, Doxorubicin, Gene Expression Profiling, Humans, Large B-Cell, Lymphoma, Oligonucleotide Array Sequence Analysis, Predictive Value of Test|
Diffuse large B-cell lymphoma (DLBCL), the most common lymphoid malignancy in adults, is curable in less than 50% of patients. Prognostic models based on pre-treatment characteristics, such as the International Prognostic Index (IPI), are currently used to predict outcome in DLBCL. However, clinical outcome models identify neither the molecular basis of clinical heterogeneity, nor specific therapeutic targets. We analyzed the expression of 6,817 genes in diagnostic tumor specimens from DLBCL patients who received cyclophosphamide, adriamycin, vincristine and prednisone (CHOP)-based chemotherapy, and applied a supervised learning prediction method to identify cured versus fatal or refractory disease. The algorithm classified two categories of patients with very different five-year overall survival rates (70% versus 12%). The model also effectively delineated patients within specific IPI risk categories who were likely to be cured or to die of their disease. Genes implicated in DLBCL outcome included some that regulate responses to B-cell-receptor signaling, critical serine/threonine phosphorylation pathways and apoptosis. Our data indicate that supervised learning classification techniques can predict outcome in DLBCL and identify rational targets for intervention.